Krystal Biotech, Inc. $KRYS Shares Sold by Atle Fund Management AB

Atle Fund Management AB reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 19.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,853 shares of the company’s stock after selling 8,338 shares during the period. Krystal Biotech makes up approximately 2.6% of Atle Fund Management AB’s investment portfolio, making the stock its 13th biggest holding. Atle Fund Management AB’s holdings in Krystal Biotech were worth $8,346,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. EFG Asset Management North America Corp. raised its holdings in shares of Krystal Biotech by 18.4% during the third quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after purchasing an additional 4,217 shares during the last quarter. Public Sector Pension Investment Board raised its holdings in shares of Krystal Biotech by 15.9% during the third quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock worth $17,729,000 after purchasing an additional 13,743 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Krystal Biotech by 469.9% during the fourth quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after purchasing an additional 15,591 shares during the last quarter. William Blair Investment Management LLC increased its holdings in Krystal Biotech by 63.9% in the third quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock valued at $26,356,000 after buying an additional 58,203 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Krystal Biotech in the third quarter valued at $1,450,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 0.5%

Shares of NASDAQ KRYS opened at $293.30 on Wednesday. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $319.48. The stock has a market cap of $8.65 billion, a PE ratio of 39.21 and a beta of 0.50. The company has a 50-day moving average of $269.52 and a 200 day moving average of $255.22.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 7.98 EPS for the current fiscal year.

Insider Activity

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at approximately $5,985,141.60. This represents a 3.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the transaction, the insider owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 116,664 shares of company stock valued at $31,136,828. Company insiders own 13.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Guggenheim lifted their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. HC Wainwright reissued a “buy” rating and set a $310.00 target price on shares of Krystal Biotech in a research note on Monday. Finally, Wolfe Research started coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating for the company. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.